A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

NCT04162327 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: IBI315
DRUG: IBI315

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.